Our purpose was to evaluate the safety and efficacy of 68 Ga-DOTATATE PET/CT compared with 111 In-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and gastroenteropancreatic neuroendocrine tumors. Methods: 68 Ga-DOTATATE PET/CT and 111 In-pentetreotide scans were obtained for 78 of 97 consecutively enrolled patients with known or suspected pulmonary or gastroenteropancreatic neuroendocrine tumors. Safety and toxicity were measured by comparing vital signs, serum chemistry values, or acquisition-related medical complications before and after 68 Ga-DOTATATE injection. Added value was determined by changes in treatment plan when 68 Ga-DOTATATE PET/CT results were added to all prior imaging, including 111 In-pentetreotide. Interobserver reproducibility of 68 Ga-DOTATATE PET/CT scan interpretation was measured between blinded and nonblinded interpreters. Results: 68 Ga-DOTATATE PET/CT and 111 In-pentetreotide scans were significantly different in impact on treatment (P , 0.001). 68 Ga-DOTATATE PET/CT combined with CT or liver MRI changed care in 28 of 78 (36%) patients. Interobserver agreement between blinded and nonblinded interpreters was high. No participant had a trial-related event requiring treatment. Mild, transient events were tachycardia in 1, alanine transaminase elevation in 1, and hyperglycemia in 2 participants. No clinically significant arrhythmias occurred. 68 Ga-DOTATATE PET/CT correctly identified 3 patients for peptidereceptor radiotherapy incorrectly classified by 111 In-pentetreotide. Conclusion: 68 Ga-DOTATATE PET/CT was equivalent or superior to 111 In-pentetreotide imaging in all 78 patients. No adverse events requiring treatment were observed. 68 Ga-DOTATATE PET/CT changed treatment in 36% of participants. Given the lack of significant toxicity, lower radiation exposure, and improved accuracy compared with 111 In-pentetreotide, 68 Ga-DOTATATE imaging should be used instead of 111 In-pentetreotide imaging where available.
Neur oendocrine tumors (NETs) are usually slow-growing malignancies, mostly of the respiratory and digestive tracts, that cause significant morbidity and mortality (1) . Although generally considered rare because of low incidence of 2.5-5/100,000 in the United States, NETs have a higher prevalence (112,000 cases) than more aggressive and common malignancies, such as pancreatic or gastric adenocarcinoma (2) . NETs can be difficult to diagnose because of protean clinical presentations. Common chronic symptoms include cough or diarrhea, whereas others are clinically silent. The average time from symptom onset to diagnosis can be up to 9 y (3). Despite its reputation as a relatively benign disease, NETs are highly metastatic, with most bronchopulmonary and small intestinal cases presenting with metastatic disease (4) . NETs have many treatment options, which differ significantly from adenocarcinomas. Surgery is the primary treatment with the best opportunity for cure and can also mitigate tumor/hormone load from metastatic burden (5) . Other treatments include systemic therapy with somatostatin analogs, biologics, molecularly targeted therapies, peptide-receptor radionuclide therapy (PRRT), liver-directed therapy, and platinumdoublet chemotherapy (6) (7) (8) (9) (10) (11) .
Given the range of treatments, it is critical to accurately delineate the extent of disease for proper management. Imaging plays an essential role in staging by showing local extent and distant disease. Conventional imaging, such as CT and MRI, provides critical information but is limited in its field of view and is highly dependent on protocol choice (12) (13) (14) (15) . Functional imaging with radiopharmaceuticals is an important diagnostic tool because most NETs have high cell surface somatostatin receptor expression levels (16) . Using somatostatin analogs conjugated to 111 In allows whole-body imaging with planar or SPECT, or SPECT/CT (17) , the gold-standard for NET imaging for more than 2 decades (18, 19) . However, PET/CT, developed in this interim, has higher resolution than SPECT. In oncology, 18 F-FDG PET/CT is the imaging reference for most malignancies. Outside the United States, PET/CT with somatostatin analogs conjugated to the positronemitting radioisotope 68 Ga is rapidly replacing 111 In-pentetreotide imaging (20) (21) (22) (23) .
The purpose of this study was to evaluate toxicity related to administration of 68 Ga-DOTATATE, a somatostatin analog with nearexclusive and high-affinity binding to somatostatin receptor subtype 2A (24) and to compare the incremental value of 68 Ga-DOTATATE compared with 111 In-pentetreotide imaging.
MATERIALS AND METHODS

Patient Population
This study is investigator-initiated with extramural (VA Merit Review I01BX007080, Society 111 In-pentetreotide imaging (n 5 87), diagnostic CT (n 5 91), and MRI of the liver (n 5 60). Participants were excluded from comparison of 68 Ga-DOTATATE with 111 In-pentetreotide scanning if no prior 111 In-pentetreotide scan was available, no 111 In-pentetreotide scan was available after a major surgical intervention occurring between 111 In-pentetreotide and 68 Ga-DOTATATE scans, or if the time between 111 In-pentetreotide and 68 Ga-DOTATATE scans exceeded 3 y. Safety and toxicity were assessed with preinjection and postimaging vital signs, pulse oximetry on room air, 12-lead electrocardiographs, and blood laboratory tests, including tumor markers, liver and renal functions, and blood counts, and direct patient questioning.
Imaging Protocol
Local synthesis of individual doses of 68 Ga-DOTATATE was performed as previously described. Radiation exposure to the patient is less than that from comparable 111 In-pentetreotide or 18 F-FDG PET/CT scans (25) . No special dietary or activity restrictions were needed because 68 Ga-DOTATATE binds almost exclusively to somatostatin receptor 2A, which is not influenced by diet or activity (26) . The mass of injected 68 Ga-DOTATATE peptide was 50 mg or less. Long-acting somatostatin analog medications are useful for symptomatic control and for antiproliferative therapy of NETs. Thus, patients on long-acting somatostatin analog medications (n 5 51) did not stop these medications before undergoing 68 Ga-DOTATATE PET/CT.
Imaging was performed with an 8-slice Discovery STE PET/CT full-ring integrated scanner (GE Healthcare), beginning 65 min (range, 55-93 min) after injection. Immediately after patients emptied their urinary bladders, low-dose CT was performed from skull vertex to mid thighs for attenuation correction and anatomic localization. Emission imaging (3-dimensional mode, 4 min per bed) was then performed from mid thighs to skull vertex, with attenuation correction performed with the manufacturer's workstations and software. Total time from injection to scan completion was less than 2 h. CT reconstruction used filtered backprojection, with emission image reconstruction via ordered-subset expectation maximization iterative reconstruction, 2 iterations, with correction for scatter and randoms as previously reported (25) .
Image Analysis
Many of our patients were not from our local area and brought conventional (CT, MRI) and 111 In-pentetreotide imaging results from outside facilities with them in digital format. All outside images and original reports were loaded onto the Vanderbilt University Medical Center's PACS linked to the Vanderbilt electronic health care records of each patient.
Because it was neither feasible nor ethical to obtain histologic confirmation of all sites of apparent metastatic tumor, diagnosis and impact on care for 68 Ga-DOTATATE versus 111 In-pentetreotide imaging was analyzed on a per-patient, not a per-lesion, basis. The diagnosis and scoring for the extent of disease was determined using a combination of the preponderance of evidence from conventional imaging and pathologic specimens before 68 Ga-DOTATATE imaging and then adding 68 Ga-DOTATATE scan results to the full clinical assessment of the patient using all available prior imaging and clinical information, to determine whether the addition of the 68 Ga-DOTATATE scan changed the treatment plan. Evidence for tumor was scored on the basis of original reports from conventional imaging as well as abnormal, especially focal, areas of uptake on 111 In-pentetreotide or 68 Ga-DOTATATE imaging. Scan results from the 3 independent 68 Ga-DOTATATE interpreters were entered into a spreadsheet, along with the original reports on conventional and 111 In-pentetreotide imaging, and then analyzed for the presence or absence of tumor, tumor improved, and stable or progressive disease compared with earlier scans, and whether, and how, the results of the 68 Ga-DOTATATE PET/CT scan changed patient management compared with either 111 In-pentetreotide alone or in combination with CT or MRI. Changes in management decision were determined and recorded via consensus of a weekly multidisciplinary NET board reviewing relevant imaging and clinical information. Contingency tables were generated with sensitivity and specificity, with confidence intervals estimated by exact binomial method. Differences in diagnostic test results were measured by McNemar x 2 test and by comparison of receiver-operator curves for differences of diagnostic test accuracy.
Original clinical reports of 111 In-pentetreotide, CT, and MRI examinations were used for analysis of these examinations even if, in retrospect, additional sites of tumor were seen after comparison to 68 Ga-DOTATATE images. 68 Ga-DOTATATE imaging was interpreted via 2 methods. First, a physician board-certified in diagnostic radiology and nuclear medicine interpreted the 68 Ga-DOTATATE PET/CT, with full access to all prior imaging and clinical information. To avoid bias and to access interobserver reproducibility, 2 board-certified nuclear medicine physicians independently interpreted the 68 Ga-DOTATATE scans, blinded to all information, including other imaging, beyond knowing that the patient met enrollment criteria. The 2 blinded interpretations were recorded on a regional basis (solid organ, regional nodal, regional extranodal abdominal and pelvic involvement, extraabdominal/pelvic nodal or soft-tissue, and skeletal disease) sufficient to stage the patient's extent of disease relative to presence of tumor, resectability/extent of tumor, and intensity/presence of somatostatin receptor expression. Reviewer agreement was assessed by Fleiss k and confidence interval estimated using the bootstrap method. The 3 physicians involved with 68 Ga-DOTATATE scan interpretation each have 30 or more y of experience in medical imaging and 10 or more y of experience in PET/CT interpretation.
Separately, a board-certified oncologic surgeon assessed the impact on care by comparing the intended treatment before and after the 68 Ga-DOTATATE scan, on a per-patient basis. The initial treatment plan was formulated using all available clinical, pathologic, and imaging information, including 111 In-pentetreotide scans. This treatment plan was then reviewed after adding the information from the 68 Ga-DOTATATE scan. Minor impact in treatment was characterized by a change within a treatment modality (intermodality), such as change in plan for already planned surgery or dosage adjustment of current medications. Major impact on treatment was characterized by a change of treatment modality (intramodality). Controversial cases, especially for major changes in management, were referred to the previously mentioned multidisciplinary NET tumor board. The addition of PRRT where previously not indicated, adding or discontinuing medications, or cancellation of surgery because of evidence of greater extent of disease on the 68 Ga-DOTATATE scan are examples of major, intramodality treatment changes.
Data Analysis
Toxicity data were compiled, and individual patient test results before and after scanning were compared. Blood laboratory test values included some fasting and nonfasting results as fasting status was not recorded. The cohorts' pre-and postscan test mean, median, standard errors, and interquartile ranges are reported in Supplemental Appendix 1 (supplemental materials are available at http://jnm.snmjournals.org). Statistically significant differences in test values were assessed by paired t test and the nonparametric Wilcoxon rank-sum test. All tests were 2-sided and performed using Stata (StataCorp.). Harm was measured by the Common Toxicity Criteria (version 1) of the National Cancer Institute (http://www.accessdata.fda.gov/scripts/cder/onctools/ toxcrit1.cfm), with blood laboratory test values within the reference range having a harm level of 0. All participants were included for toxicity measurement.
RESULTS
Toxicity/Safety
No serious adverse events occurred among the 97 participants. Additional comorbidities influencing abnormal baseline, preinjection electrocardiograms included various conduction defects, 1 patient with electrocardiogram evidence of a prior anteroseptal infarction with a left anterior fascicular block, 2 patients with T-wave inversions, 2 patients with nonspecific ST-T wave changes, 2 patients with first degree AV block, 2 patients with p-wave abnormities, 1 patient with a ventricular paced rhythm, and 1 patient with a prior cardiac transplant. No serious arrhythmias, changes in Q-T interval, or other significant changes from baseline were observed.
Minor adverse events occurred in 3 patients. One had minor itching the day after the 68 Ga-DOTATATE injection at the injection site, spontaneously resolving. One patient had an unexplained drop in postscan oxygen saturation on room air (before injection, 98%; after scanning, 90%), spontaneously resolving. One patient with a baseline heart rate of 87 had postscan tachycardia of 112, asymptomatic, spontaneously returning to less than 100 beats per minute within an hour. Other patients had minor and transient changes in laboratory tests, all asymptomatic. Elevated glucose was observed in 2 patients (both on long-acting somatostatin analog medication, known to cause glucose intolerance in up to 25% of patients; 1 of these 2 patients is a diabetic). Postscan fasting glucose plasma levels could not be consistently obtained after the participants returned home, so these 2 elevated values may not have been fasting. Changes in plasma levels of some blood markers were not available in 28 individuals who did not present to the laboratory. The patient with elevation in liver function tests had known extensive liver metastases, with improvement after PRRT.
Evaluation of 68 Ga-DOTATATE Imaging and Safety
Most participants, 56 (58%), were female. Midgut NET was the most common tumor type (44, 56%) ( (Fig. 1) . One individual was false-positive by both scans, confirmed by biopsy, and 1 was false-negative by both methods, with tumor confirmed by other imaging. Among the 17 participants with scan disagreement, 111 In-pentetreotide was false-positive in 2 and 68 Ga-DOTATATE was false-positive in 1. The sensitivity of 68 Ga-DOTATATE imaging (96%; 95% CI, 86%-100%) was higher than that of 111 In-pentetreotide imaging by all methods (72%; 95% CI, 58%-84%) and was also higher (97%; 95% CI, 82%-100%) in the subgroup of patients with 111 In-pentetreotide SPECT/CT scans (83%; 95% CI, 64%-94%). 111 In-pentetreotide SPECT/CT was more sensitive than planar only or planar plus SPECT imaging of 111 In-pentetreotide. Specificity was the same for 68 Ga-DOTATATE and 111 In-pentetreotide (93%; 95% CI: 77%-99%) among all 111 In-pentetreotide scan types and also for the SPECT/CT subgroup. Overall accuracy for 68 Ga-DOTATATE (0.94; 95% CI, 0.89-1.00) was significantly higher (P 5 0.02) than for 111 In-pentetreotide (0.82; 95% CI: 0.74-0.90) ( Table 2) . 68 Ga-DOTATATE and 111 In-pentetreotide imaging did not convey the same diagnostic result (McNemar x 2 P 5 0.01) in this population of mixed NET.
Assessment of 68 Ga-DOTATATE Interobserver Variability
Bias-corrected Fleiss k was 0.82 (95% CI, 0.74-0.89) between the 3 reviewers in their interpretation of the 97 68 Ga-DOTATATE scans. This high level of agreement was similar between various combinations of blinded versus nonblinded clinical interpreters (Supplemental Table 1) , demonstrating a high level of reproducibility in 68 Ga-DOTATATE scan interpretations.
Assessment of Impact on Patient Care
The addition of the 68 Ga-DOTATATE imaging resulted in no impact on treatment plans in 50 of 78 (64%), a minor (within modality) change in 9 of 78 (12%), and a major change in treatment modality in 19 of 78 (24%) patients. Of the 19 patients with a major change due to 68 Ga-DOTATATE imaging, 8 had surgery cancelled or a radical change in type of surgery, and 12 patients were referred for PRRT (Fig. 2) . Among 48 patients with treatment changes with 111 In-pentetreotide SPECT/CT scans, 68 Ga-DOTATATE imaging led to major changes in 11 of 78 (14%). Furthermore, time between 68 Ga-DOTATATE and 111 In-pentetreotide imaging was broken into 3 categories, 0-90 d, 91-180 d, and more than 180 d (Table 3) . Changes in treatment plans were similar between the 3 time categories, with the highest proportion of scans having an impact on treatment in the 0-90 d category (44%) and least in the 91-180 d category (30%), though the differences were not significant. 68 Ga-DOTATATE and 111 In-pentetreotide scans were concurrently false-negative in 1 patient with tumor found on CT and MRI, but the 2 scans yielded useful information by demonstrating that the patient was not likely to benefit from PRRT. 68 Ga-DOTATATE imaging demonstrated that 12 of 78 (15%) patients were nonsurgical candidates, with strong uptake to support PRRT, of which 3 of 12 (25%) were misclassified by 111 In-pentetreotide as not candidates for PRRT (Fig. 3) . 68 Ga-DOTATATE PET/CT is a more sensitive functional test than 111 In-pentetreotide imaging in our 78 patients with NETs and comparative scans, with 1 false-positive scan resulting in a biopsy. 68 Ga-DOTATATE PET/CT was superior to 111 In-pentetreotide imaging in a 48-patient subset with 111 In-pentetreotide SPECT/CT scans.
In 12 patients found by 68 Ga-DOTATATE to have sufficient somatostatin receptor expression to support PRRT, 3 were misclassified by 111 In-pentetreotide and would have been denied PRRT, a treatment currently under study for benefit. We found that correct clinical management could be made in all patients with imaging limited to 68 Ga-DOTATATE plus diagnostic CT or contrast-enhanced liver MRI, excluding the 1 false-positive examination from splenosis. No patient management decisions would have been adversely affected by excluding the 111 In-pentetreotide scan, whereas 28 of 78 (36%) patients would have been adversely affected if the 68 Ga-DOTATATE scan had not been obtained. The 111 In-pentetreotide scans were not of uniform quality, reflecting the range of protocols and equipment in the U.S. health care system. Some were performed with planar imaging only, some with planar and SPECT imaging, and some with planar and SPECT/CT. The planar with SPECT/CT imaging group provided the best comparison to 68 Ga-DOTATATE PET/CT. Accordingly, we performed a subanalysis comparing these 2 imaging modalities ( Table 3 ). The results of this subanalysis showed that the accuracy of 111 In-pentetreotide SPECT/CT was higher than that of planar or planar with SPECT but was not as accurate as 68 Ga-DOTATATE PET/CT, with much of this difference driven by the number of malignant lesions missed by 111 In-pentetreotide, seen by 68 Ga-DOTATATE, especially in lymph nodes, intramedullary skeletal metastases, and distant (extraabdominal) metastases. This difference in test accuracy is also reflected in the 19 patients who had major changes in their treatment plans because of additional metastatic disease detected with 68 Ga-DOTATATE PET/CT.
One intense focus of 68 Ga-DOTATATE was in the head of the pancreas, a known area of frequent intense, focal uptake of 68 Ga-DOTATATE that can also be seen with 111 In-pentetreotide (23). Because we knew of this frequent finding, no adverse impact on care resulted, with absence of tumor confirmed by CT. The single known false-positive result was due to splenosis and inflammation, confirmed at surgery, though surgery was already planned.
Interobserver reliability between the nonblinded, fully informed 68 Ga-DOTATATE interpreter and the 2, independent, blinded interpreters demonstrated the high degree of reproducibility of interpretation in this trial by experienced interpreters on a per-patient basis. The k statistic of 0.82 represents superior to near-perfect agreement between the 3 interpreters.
This study has some limitations. As it is neither feasible nor ethical to obtain histologic confirmation of all sites of apparent tumor, the impact on care for 68 Ga-DOTATATE versus 111 In-pentetreotide imaging was analyzed on a per-patient, not a per-lesion, basis. The 68 Ga-DOTATATE scan was added to the full clinical assessment of the patient performed before the 68 Ga-DOTATATE scan, using all prior imaging and clinical information, to determine whether the addition of the 68 Ga-DOTATATE scan changed the treatment plan, similar to other reports (23, 28, 31) . The sensitivity and specificity of both 111 In-pentetreotide and 68 Ga-DOTATATE in our trial may not reflect the true accuracy of either test because of an imperfect gold standard bias arising from using per-patient rather than per-lesion analysis. To minimize the bias from this imperfect gold standard, we focused on comparing clinical management impact rather than the possibly imperfect final diagnosis (32) . Importantly, this is the first report, to our knowledge, with quantitative toxicity data for 68 Ga-DOTATATE, with prior reporting typically limited to general observation due to differences in regulatory requirements for investigators outside the United States for drug mass microdose quantities (33) . Although acute toxicity data were available in all 97 patients, our study is limited by some random postscan organ function or hematologic toxicity All 111 In-pentetretotide scan types, n 5 78, and 111 In-pentetretotide with SPECT/CT, n 5 48. There was no significant impact on care by time interval between scans. data missing in 28 patients. Many patients traveled great distances to us, limiting our access to follow-up laboratory tests, especially in a timely manner. However, in the data we have for all 97 patients, we observed no toxicity that was symptomatic or otherwise requiring treatment.
Another limitation of our study is that not all patients had identical imaging protocols for CT, MRI, or 111 In-pentetreotide scanning. Not all had both CT and MRI examinations, and the quality of the outside studies reflected the range in image quality throughout the United States. Also, because not all of our patients had health care insurance, not all could afford the requested followup laboratory tests.
CONCLUSION
68 Ga-DOTATATE PET/CT changed management in 37% of patients. 111 In-pentetreotide did not add value compared with 68 Ga-DOTATATE in any patient. When diagnostic imaging is limited to whole-body 68 Ga-DOTATATE plus diagnostic CT or liver MRI, correct staging and treatment decisions would have been reached in all patients. Our results clearly demonstrate that 68 Ga-DOTATATE PET/ CT is equivalent or superior to 111 In-pentetreotide imaging for the diagnosis and staging of lung and gastroenteropancreatic NETs. Given the superior performance for tumor detection (McNemar x 2 , P 5 0.01), lower radiation dosimetry (25) , and 2-h completion time compared with 2 d for 111 In-pentetreotide imaging, our results conclusively demonstrate that 68 Ga-DOTATATE PET/CT imaging is safe and should replace 111 In-pentetreotide imaging, where available.
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